Description:
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy.
- Molecular Weight:439.57
- Purity:≥98%
Molecular Formula:
C25H29NO4S
Canonical SMILES:
CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
InChI:
InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1
InChIKey:
MRWFZSLZNUJVQW-DEOSSOPVSA-N
Solubility:
Soluble in DMSO
Appearance:
Red Gel
Storage: Store at -20 °C
Synonyms:
Lipaglyn; ZY-H1; (αS)-α-Ethoxy-4-[2-[2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic Acid Weitere Informationen finden Sie
hier